Microplate Dx Limited is at the forefront of combating antimicrobial resistance (AMR) through its innovative technologies aimed at rapid antibiotic susceptibility testing (AST). The company has developed a unique solution that integrates advanced hardware with sophisticated data processing algorithms, specifically designed for testing urinary tract infections. Their flagship product, RapidPlate, has demonstrated impressive performance, achieving 96% accuracy with results available in just 30 minutes during pre-clinical studies. This rapid testing capability is crucial in addressing the growing threat of AMR, which could lead to millions of deaths by 2050 if not effectively managed.

The Microplate Dx team comprises experts from diverse fields, including medicine, science, engineering, and technology, all united by a commitment to advancing diagnostic solutions. Their ongoing efforts have garnered significant investment, including a recent £2.5 million funding round aimed at further developing their technologies. By focusing on rapid and accurate testing methods, Microplate Dx is positioning itself as a key player in the fight against AMR, striving to safeguard public health and improve patient outcomes through timely and effective diagnostics.

United Kingdom

Microplate Dx Limited specialises in rapid antibiotic susceptibility testing diagnostics, enabling clinicians, at the point-of-care, to confidently select the best choice of antibiotic to treat a patient's infection in a matter of minutes, significantly quicker than the current gold standard technology which takes at least 2 days. Our award-wining, platform diagnostic test helps reduce the major global health threat of antimicrobial resistance and ultimately, saves lives.

Microplate Dx Limited

Company Details